Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.56 |
| ▸ | JAK3 | P52333 | 9/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456047 | 0.88 | JAK2 (0.58) | JAK2JAK3KDRPTK2CSF1R | |
| SCHEMBL14024424 | 0.79 | JAK2 (0.51) | JAK2JAK3KDRCSF1RTYK2 | |
| SCHEMBL4779158 | 0.79 | CSF1R (0.51) | JAK2JAK3KDRPTK2CSF1R | |
| SCHEMBL4875509 | 0.79 | PLK4 (0.64) | JAK2JAK3KDRPTK2CSF1R | |
| SCHEMBL27684493 | 0.77 | KDM4E (0.49) | JAK2JAK3CYP2C9CYP2C19 | |
| SCHEMBL14048207 | 0.77 | KDR (0.65) | JAK2JAK3KDRCYP3A4CYP2C9 | |
| SCHEMBL4732552 | 0.75 | KDR (0.75) | KDR | |
| SCHEMBL14024633 | 0.75 | KDR (0.45) | JAK2JAK3KDRCSF1RTYK2 | |
| SCHEMBL15939450 | 0.75 | KDR (0.55) | KDR | |
| SCHEMBL15829985 | 0.75 | ALDH1A1 (0.57) | RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | JAK2 910/4885JAK3 1979/4885KDR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.